Abstract: The present invention relates to a method of sequence-specific recombination of DNA in eukaryotic cells, comprising the introduction of a first DNA comprising a nucleotide sequence containing at least one recombination sequence into a cell, introducing a second DNA comprising a nucleotide sequence containing at least one further recombination sequence into a cell, and performing the sequence specific recombination by a bacteriophage lambda integrase Int.

Abstract: A pharmaceutical composition comprising: (a) an anticholinergic selected from glycopyrronium bromide or an ester of a bi- or tricyclic amino alcohol of formula (I) wherein: Q, R, R?, and Z are defined in the claims and an equivalent of an anion X counters the positive charge of the N atom; and (b) a betamimetic selected from the group consisting of: formoterol; salmeterol; 4-hydroxy-7-[2-{[2-{[3-(2-phenylethoxy)propyl]sulfonyl}ethyl]amino}ethyl]-2(3H)-benzothiazolone; 1-(2-fluoro-4-hydroxyphenyl)-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]ethanol; 1-[3-(4-methoxybenzylamino)-4-hydroxyphenyl]-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]ethanol; 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-N,N-dimethylaminophenyl)-2-methyl-2-propylamino]ethanol; 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-methoxyphenyl)-2-methyl-2-propylamino]ethanol; 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino]ethanol; and 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxa

Abstract: The present invention relates to pharmaceutical preparations in the form of aqueous solutions for the production of propellant-free aerosols.

Abstract: The invention relates to capsules for inhalation (inhalettes) made from specific capsule materials with a reduced moisture content, which contain the active substance tiotropium in the form of powdered preparations and are characterised by increased stability.

Abstract: The present invention relates to pharmaceutical preparations in the form of aqueous solutions for the production of propellant-free aerosols.

Abstract: The present invention relates to a method of sequence-specific recombination of DNA in eukaryotic cells, comprising the introduction of a first DNA comprising a nucleotide sequence containing at least one recombination sequence into a cell, introducing a second DNA comprising a nucleotide sequence containing at least one further recombination sequence into a cell, and performing the sequence specific recombination by a bacteriophage lambda integrase Int.

Abstract: A process for the production of a container (1) comprising an outer container (2), an inner bag (3) disposed therein and a pressure equalisation opening (10) disposed in the outer container (2), and also a container (1) produced according to this process, is described, wherein firstly a pre-moulding, comprising two coaxial tubes, is first produced by co-extrusion with the help of a blow mould and with an outwardly-projecting base seam (5) being formed. The process is to form a pressure equalisation opening (10) in the outer container (2) of the container (1) without endangering the integrity of the container (1), wherein a lower wastage rate and higher productivity are to be achieved. This is attained by a process wherein the base seam (5) is partially cut off and a force which acts in the direction of the seam is introduced into the pre-moulding, which still has a temperature of 40° C. to 70° C.

Abstract: The present invention relates to substituted xanthines of general formula wherein R1 to R3 are defined as in claims 1 to 16, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Abstract: The present invention relates to substituted xanthines of general formula wherein R1 to R3 are defined as in claims 1 to 16, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Abstract: The present invention relates to carboxylic acid amides of general formula wherein R1 to R5, Ar, m and n are defined as in claim 1, the tautomers, stereoisomers, mixtures thereof, the prodrugs and the salts thereof which have valuable properties. The compounds of the above general formula I wherein R5 denotes a cyano group are valuable intermediate products for preparing the other compounds of general formula I, and the compounds of the above general formula I wherein R5 denotes one of the amidino groups mentioned in claim 1 have valuable pharmacological properties, particularly an antithrombotic activity and a factor Xa-inhibiting activity.

Abstract: The invention relates to the polymorph A of flibanserin, to a technical process for the preparation thereof, as well as to the use thereof for preparing medicaments.

Abstract: A process for the production of a container comprising an outer container, an inner bag disposed therein and a pressure equalisation opening disposed in the outer container, and also a container produced according to this process, is described, wherein firstly a pre-moulding, comprising two coaxial tubes, is first produced by co-extrusion with the help of a blow mould and with an outwardly-projecting base seam being formed. The process is to form a pressure equalisation opening in the outer container of the container without endangering the integrity of the container, wherein a lower wastage rate and higher productivity are to be achieved. This is attained by a process wherein the base seam is partially cut off and a force which acts in the direction of the seam is introduced into the pre-moulding, which still has a temperature of 40 degrees C. to 70 degrees C., which force breaks open and plastically deforms the base seam so that a pressure equalisation opening is formed in the base area.

Abstract: The invention relates to the use of (1?,2?,4?,5?,7?)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane salts for preparing a pharmaceutical composition for the prevention and treatment of diseases associated with inflammation.

Abstract: A pharmaceutical composition, comprising: (a) a tiotropium salt (1); and (b) a salmeterol salt (2), optionally in the form of the enantiomers, mixtures of enantiomers, or in the form of the racemates thereof, optionally in the form of the solvates or hydrates and optionally together with a pharmaceutically acceptable excipient, and methods of treating respiratory diseases using such a pharmaceutical composition.

Abstract: The present invention relates to pharmaceutical preparations in the form of aqueous solutions for the production of propellant-free aerosols.

Abstract: The invention relates to the use of flibanserin, or a pharmaceutically acceptable acid addition salt thereof, for the treatment of disorders of sexual desire.

Abstract: A process which can be used in the laboratory or on an industrial scale for cleaning the inner wall of hard gelatine capsules, in which the sealed capsules are cleaned with a powder formulation.

Abstract: The invention relates to the use of flibanserin, or a pharmaceutically acceptable acid addition salt thereof, for the treatment of disorders of sexual desire.

Abstract: The invention relates to a crystalline sodium salt of 4?-[2-n-propyl-4-methyl-6-(1-methyl-benzimidazol-2-yl)benzimidazol-1-ylmethyl]biphenyl-2-carboxylic acid (INN: telmisartan), processes for preparing it and the use thereof for preparing a pharmaceutical composition.

Abstract: The invention concerns an improved therapeutic regimen for the treatment of thrombolytic disorders, such as acute myocardial infarction (AMI). In particular, the present invention concerns the treatment of thrombolytic disorders, e.g. AMI, with a combination of a tissue plasminogen activator (t-PA) variant having improved fibrin specificity and extended plasma half-life when compared with wild-type human t-PA and a low molecular weight heparin.